Market Positioning Viridian is advancing a potentially best-in-class IV TED therapy (Lumvoa) with a concurrent SC candidate (VRDN-003), positioning it to compete with established players in a high-value niche and presenting a direct sales opportunity for specialty distributors, payers, and hospital systems focused on thyroid eye disease.

Launch Readiness FDA approval and immediate launch of Lumvoa create near-term sales momentum and demand generation opportunities with patient assistance programs (ViridianCares) that can be bundled with payer outreach, channel partnerships, and hospital procurement strategies.

Strategic Partnerships Recent WuXi Biologics collaboration for manufacturing fortifies supply chain credibility and opens doors for co-development discussions, enabling BD teams to pitch scalable manufacturing and risk-mitigated commercialization to potential global partners.

Expansion Potential A growing portfolio beyond TED, including FcRn inhibitors VRDN-006 and VRDN-008 and an anti-TSHR program, signals multiple adjacent indications and aging patient populations, suggesting cross-sell and portfolio-based contracting opportunities with specialty clinics and autoimmune disease networks.

Global Reach Strategic Japan licensing with Kissei Pharmaceutical expands geographic access and channel strategies, creating co-promotion and market-access opportunities that can be leveraged to accelerate payer acceptance and regional sales planning.